AAPL 206.655 1.0044% MSFT 384.86 2.7965% NVDA 106.185 3.3833% GOOGL 158.72 2.1693% GOOG 160.73 1.9084% AMZN 185.5673 2.7504% META 530.91 2.0451% AVGO 187.43 5.9465% BRK-A 795500.0 0.8495% BRK-B 530.135 0.6312% LLY 855.05 3.0901% TSLA 255.535 1.9123% TSM 163.78 3.783% V 336.305 0.5787% JPM 243.935 1.2683% UNH 426.3 -0.3879% NVO 62.61 2.137% WMT 95.78 0.8635% LVMUY 113.69 1.6632% XOM 108.77 1.3039%
Last update at 2024-09-11T11:49:09.428271Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -22.72700M | -8.47700M | -4.72300M | -6.23000M | 9.64M |
| Minority interest | - | - | - | - | - |
| Net income | -37.66900M | -8.36800M | -5.11800M | -6.04200M | 4.19M |
| Selling general administrative | 8.23M | 5.92M | 4.76M | 6.62M | 8.89M |
| Selling and marketing expenses | 8.23M | 1.35M | 1.13M | 1.21M | 3.11M |
| Gross profit | 5.48M | 5.17M | 1.33M | 0.12M | 24.78M |
| Reconciled depreciation | 0.14M | 0.14M | 0.23M | 0.32M | 0.06M |
| Ebit | -15.25300M | -8.67100M | -6.06400M | -9.54400M | 8.92M |
| Ebitda | -7.64700M | -8.52600M | -7.90900M | -9.22900M | 8.98M |
| Depreciation and amortization | 7.61M | 0.14M | -1.84500M | 0.32M | 0.06M |
| Non operating income net other | - | - | - | - | - |
| Operating income | -15.25300M | -8.67100M | -6.06400M | -9.54400M | 9.84M |
| Other operating expenses | 20.89M | 13.93M | 9.72M | 10.08M | 17.04M |
| Interest expense | 0.00300M | 0.02M | 3.42M | 0.59M | 0.28M |
| Tax provision | 0.00000M | -0.10900M | 0.40M | -0.18800M | 5.45M |
| Interest income | - | - | - | 4.61M | 0.28M |
| Net interest income | -0.00300M | -0.02100M | -0.73600M | -0.59300M | 0.28M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 14.94M | -0.10900M | 0.40M | -0.18800M | 5.45M |
| Total revenue | 5.64M | 5.26M | 3.65M | 0.53M | 26.88M |
| Total operating expenses | 20.74M | 13.84M | 7.40M | 9.67M | 14.94M |
| Cost of revenue | 0.16M | 0.09M | 2.32M | 0.41M | 2.10M |
| Total other income expense net | -7.47400M | 0.19M | 1.34M | 3.31M | -0.48100M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -22.72700M | -8.36800M | -5.11800M | -6.04200M | 4.19M |
| Net income applicable to common shares | - | -8.36800M | -5.11800M | -6.04200M | 4.19M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 36.83M | 56.03M | 80.10M | 37.28M | 19.98M |
| Intangible assets | - | - | 0.62M | 0.06M | 0.04M |
| Earning assets | - | - | - | - | - |
| Other current assets | 1.93M | 2.49M | 1.77M | 0.87M | 1.21M |
| Total liab | 18.72M | 20.25M | 27.12M | 24.07M | 22.44M |
| Total stockholder equity | 18.10M | 35.78M | 52.99M | 13.21M | -2.46300M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 2.28M | 1.94M | 1.89M | 1.50M | 2.93M |
| Common stock | 291.91M | 293.41M | 293.41M | 235.01M | 224.53M |
| Capital stock | 293.41M | 293.41M | 293.41M | 235.01M | 224.53M |
| Retained earnings | -367.93883M | -352.08400M | -334.61900M | -322.65900M | -316.89100M |
| Other liab | - | - | 19.32M | 19.00M | 16.53M |
| Good will | - | 0.00000M | 8.13M | 8.81M | 8.05M |
| Other assets | 0.00000M | - | 0.34M | 0.34M | 0.36M |
| Cash | 33.84M | 50.61M | 65.30M | 24.27M | 7.84M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 4.52M | 7.04M | 7.77M | 5.01M | 5.66M |
| Current deferred revenue | 0.22M | 2.95M | 4.82M | 2.19M | 0.99M |
| Net debt | -33.56439M | -50.43200M | -65.13900M | -24.08700M | -6.93500M |
| Short term debt | 0.16M | 0.11M | 0.13M | 0.14M | 0.65M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 0.28M | 0.18M | 0.16M | 0.18M | 0.90M |
| Other stockholder equity | 90.25M | 95.42M | 94.87M | 101.91M | 89.81M |
| Property plant equipment | - | - | 0.19M | 0.18M | 0.62M |
| Total current assets | 36.18M | 55.49M | 70.82M | 27.89M | 10.91M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | - | 44.23M | 4.34M | -10.55300M |
| Short term investments | - | - | - | - | - |
| Net receivables | 0.34M | 2.16M | 3.67M | 1.68M | 0.66M |
| Long term debt | - | - | - | - | - |
| Inventory | 0.07M | 0.23M | 0.07M | 0.02M | 1.20M |
| Accounts payable | 1.86M | 2.04M | 0.93M | 1.19M | 1.09M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 3.89M | -0.96700M | -0.67800M | -1.04500M | 0.09M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | 235.01M | 224.53M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | - | - | - |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 0.33M | 0.32M | 0.34M | 0.34M | 0.36M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 0.65M | 0.54M | 9.28M | 9.39M | 9.07M |
| Capital lease obligations | 0.28M | 0.18M | 0.16M | 0.18M | 0.90M |
| Long term debt total | - | - | - | - | 0.26M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -0.01200M | -0.65800M | 0.06M | 0.05M | -0.03500M |
| Change to liabilities | - | 3.64M | 3.08M | 0.13M | -0.18600M |
| Total cashflows from investing activities | - | -0.65800M | 0.06M | 0.05M | -0.03500M |
| Net borrowings | - | -0.12700M | -0.26500M | -0.61400M | -0.61400M |
| Total cash from financing activities | -0.11800M | 51.04M | 20.47M | 3.89M | 3.89M |
| Change to operating activities | - | -1.09900M | -1.23400M | -1.04200M | -1.85300M |
| Net income | -22.72700M | -8.36800M | -5.11800M | -6.04200M | 4.19M |
| Change in cash | -14.68900M | 41.03M | 16.43M | -6.67400M | 6.73M |
| Begin period cash flow | 65.30M | 24.27M | 7.84M | 14.51M | 7.78M |
| End period cash flow | 50.61M | 65.30M | 24.27M | 7.84M | 14.51M |
| Total cash from operating activities | -13.68000M | -8.58100M | -4.12900M | -10.72500M | 6.83M |
| Issuance of capital stock | 0.00000M | 34.20M | 23.50M | 4.99M | 0.00000M |
| Depreciation | 0.14M | 0.14M | 0.23M | 0.32M | 0.06M |
| Other cashflows from investing activities | - | -0.02000M | 0.05M | 0.05M | -0.05000M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -0.16100M | -0.05600M | 1.18M | -0.97100M | 0.31M |
| Change to account receivables | - | -0.73900M | -1.33000M | -0.72900M | 2.17M |
| Sale purchase of stock | - | - | - | 5.30M | - |
| Other cashflows from financing activities | 0.02M | 16.96M | -2.76700M | -0.48100M | -0.03500M |
| Change to netincome | - | -2.85800M | -2.37700M | -3.10400M | 2.73M |
| Capital expenditures | 0.01M | 0.64M | 0.03M | 0.03M | 0.00900M |
| Change receivables | - | - | - | - | - |
| Cash flows other operating | - | - | - | - | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - | - |
| Change in working capital | 0.60M | 2.50M | 2.40M | -2.44400M | -0.15100M |
| Stock based compensation | 0.54M | 0.31M | 0.06M | 0.79M | 0.57M |
| Other non cash items | 7.76M | -1.56800M | 1.88M | 0.28M | -1.31800M |
| Free cash flow | -13.69100M | -9.22000M | -4.12900M | -10.72500M | 6.82M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AEZS Aeterna Zentaris Inc |
- -% | - | - | - | 2.20 | 0.53 | 0.16 | 1.34 |
| NVO Novo Nordisk A/S |
1.31 2.14% | 62.61 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
1.30 2.09% | 63.55 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
-1.42 0.29% | 491.00 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
2.92 0.50% | 590.76 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis. The company also has a license and research agreement with University of Wuerzburg to develop, manufacture, and commercialize AIM biologicals for the treatment of neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson's disease. In addition, it has a license agreement with Consilient Health Ltd. and NK MEDITECH Ltd. for the development and commercialization of macimorelin; a distribution and commercialization agreement with Er-Kim Pharmaceuticals Bulgaria Eood for the commercialization of macimorelin for the diagnosis of growth hormone deficiency in children and adults; as well as The University of Sheffield, the United Kingdom for the development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of chronic hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Toronto, Canada.
315 Sigma Drive, Summerville, SC, United States, 29486
| Name | Title | Year Born |
|---|---|---|
| Dr. Klaus Paulini Ph.D. | Pres, CEO & Exec. Director | NA |
| Dr. Nicola Ammer M.D. | Chief Medical Officer & Sr. VP of Clinical Devel. | NA |
| Dr. Matthias Gerlach | Sr. VP Manufacturing & Supply Chain | NA |
| Mr. Giuliano La Fratta | Sr. VP of Fin. & CFO | NA |
| Dr. Michael Teifel | Sr. VP of Non-Clinical Devel. & Chief Scientific Officer | NA |
| Dr. Eckhard G. Guenther Ph.D. | Sr. VP of Bus. Devel. & Alliance Management and MD of AEZS Germany | NA |
| Ms. Amélie Métivier | Assistant Sec. | NA |
| Dr. Klaus Paulini Ph.D. | President, CEO & Executive Director | NA |
| Mr. Giuliano La Fratta | Senior VP of Finance & CFO | NA |
| Dr. Michael Teifel Ph.D. | Senior VP of Non-Clinical Development & Chief Scientific Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US
CA
NZ
UK
AU
IND
Please wait processing your request...